Revision Total Hip Arthroplasty with Primary Stem or Full-Porous-Coated Long Stem for Aseptic Femoral Component Loosening: A Matched-Pair Study

Autor: Tsai MH, Chen CC, Chang CH, Chang Y, Hsieh PH, Hu CC

Publikováno v: Orthopedic Research and Reviews, Vol Volume 14, Pp 25-33 (2022)

Meng-Huan Tsai,1 Chun-Chieh Chen,1– 3 Chih-Hsiang Chang,1– 3 Yuhan Chang,1– 3 Pang-Hsin Hsieh,1– 3 Chih-Chien Hu1– 3 1Department of Orthopedic Surgery, Chang Gung Memorial Hospital, Taoyuan, 33305, Taiwan; 2Bone and Joint Research Center, C

Externí odkaz: https://doaj.org/article/d52d9c7c80014c9d887b2f6ee031d608

Beneficial Effect of TaON-Ag Nanocomposite Titanium on Antibacterial Capacity in Orthopedic Application

Autor: Hu CC, Chang CH, Chang Y, Hsieh JH, Ueng SWN

Publikováno v: International Journal of Nanomedicine, Vol Volume 15, Pp 7889-7900 (2020)

Chih-Chien Hu,1– 4 Chih-Hsiang Chang,1– 3 Yuhan Chang,1– 3 Jang-Hsing Hsieh,5,6 Steve Wen-Neng Ueng1– 3 1Bone and Joint Research Center, Chang Gung Memorial Hospital, Kweishan, Taoyuan 33305, Taiwan; 2Department of Orthopedic Surgery, Chang G

Externí odkaz: https://doaj.org/article/dc23ededadbf41919d1e8699017aa281

Blood lead level is a positive predictor of uremic pruritus in patients undergoing hemodialysis

Autor: Weng CH, Hsu CW, Hu CC, Yen TH, Chan MJ, Huang WH

Publikováno v: Therapeutics and Clinical Risk Management, Vol Volume 13, Pp 717-723 (2017)

Cheng-Hao Weng,1,2 Ching-Wei Hsu,1,2 Ching-Chih Hu,2,3 Tzung-Hai Yen,1,2 Ming-Jen Chan,1,2 Wen-Hung Huang1,2 1Department of Nephrology and Division of Clinical Toxicology, Chang Gung Memorial Hospital, Linkou Medical Center, 2Department of Medicine,

Externí odkaz: https://doaj.org/article/87dbc7fff8c24598a63a13eb6e17dfb3

Association between ambient carbon monoxide and secondary hyperparathyroidism in nondiabetic patients undergoing peritoneal dialysis

Autor: Weng CH, Hu CC, Yen TH, Huang WH

Publikováno v: Therapeutics and Clinical Risk Management, Vol 2015, Iss default, Pp 1401-1408 (2015)

Cheng-Hao Weng,1,2 Ching-Chih Hu,3 Tzung-Hai Yen,1,2 Wen-Hung Huang1,2 1Department of Nephrology, Division of Clinical Toxicology, Chang Gung Memorial Hospital, Linkou, 2College of Medicine, Chang Gung University, Taoyuan, 3Liver Research Unit, Depar

Externí odkaz: https://doaj.org/article/f1e8b77a43474c7c98df14f398a70ffe

Apremilast, ein oraler PDE-4-Inhibitor, führt bei Patienten mit Psoriasisarthritis zu langfristigen (104-wöchigen) Verbesserungen von Enthesitis und Daktylitis – Gepoolte Ergebnisse dreier randomisierter, kontrollierter, Phase-III-Studien (PALACE 1-3)

Autor: Gladman, D, Hall, S, Kavanaugh, A, Gomez-Reino, JJ, Wollenhaupt, J, Cutolo, M, Schett, G, Lespessailles, E, McIlraith, M, Hu, CC, Edwards, C, Birbara, CA, Mease, P

Publikováno v: 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20160831-20160903; Frankfurt am Main; DOCSP.08 /20160829/

Einleitung: Die Studien PALACE 1 (NCT01172938), 2 (NCT01212757), und 3 (NCT01212770) untersuchten die Wirksamkeit/Sicherheit von Apremilast bei Patienten, die trotz vorheriger Gabe konventioneller DMARDs und/oder Biologika an einer aktiven Psoriasisa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5e1177f8cc494a192eb8a4bac4e8ce4